Is Massive Scale Proteomics Causing a Paradigm Shift in Biomarker Discovery?

November 17, 2021 | 10:15 MT

ABSTRACT

In this 45-minute talk, Dr. Stefánsson will discuss the largest population proteomics study ever performed to help provide more insight on disease and health outcomes. This collaborative research assembled expertise from deCODE Genetics and SomaLogic to combine the study of genetic and protein diversity to characterize disease biomarkers in the human population. The data from this type of proteomic study will inform drug discovery and development as well as improvements in health management. You will learn about: 

  • The high-throughput technologies that made this study possible
  • The application of population proteomics in diagnosis and management of common and rare diseases

Dr. Kári Stefánsson

CEO deCode Genetics

Kári Stefánsson is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email